Ticker
ACER

Price
2.22
Stock movement up
+0.05 (2.30%)
Company name
Acer Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
43.73M
Ent value
64.89M
Price/Sales
121.48
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
3.26%
3 year return
-20.33%
5 year return
-35.15%
10 year return
-31.63%
Last updated: 2023-02-03

DIVIDENDS

ACER does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales121.48
Price to Book-
EV to Sales180.24

FINANCIALS

Per share

Loading...
Per share data
Current share count19.70M
EPS (TTM)-1.32
FCF per share (TTM)-1.65

Income statement

Loading...
Income statement data
Revenue (TTM)360.00K
Gross profit (TTM)0.00
Operating income (TTM)-23.77M
Net income (TTM)-21.27M
EPS (TTM)-1.32
EPS (1y forward)-0.61

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-6603.02%
Profit margin (TTM)-5909.34%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash6.38M
Net receivables0.00
Total current assets7.30M
Goodwill7.65M
Intangible assets0.00
Property, plant and equipment0.00
Total assets15.32M
Accounts payable4.69M
Short/Current long term debt8.25M
Total current liabilities20.79M
Total liabilities27.53M
Shareholder's equity-12.21M
Net tangible assets-19.85M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-26.38M
Capital expenditures (TTM)85.23K
Free cash flow (TTM)-26.47M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-138.82%
Return on Invested Capital515.60%
Cash Return on Invested Capital641.53%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.22
Daily high2.27
Daily low2.13
Daily Volume206K
All-time high414221.04
1y analyst estimate8.50
Beta0.68
EPS (TTM)-1.32
Dividend per share-
Ex-div date-
Next earnings date28 Feb 2023

Downside potential

Loading...
Downside potential data
ACERS&P500
Current price drop from All-time high-100.00%-13.68%
Highest price drop-100.00%-56.47%
Date of highest drop1 Dec 20229 Mar 2009
Avg drop from high-98.82%-11.49%
Avg time to new high418 days13 days
Max time to new high4556 days1805 days
COMPANY DETAILS
ACER (Acer Therapeutics Inc) company logo
Marketcap
43.73M
Marketcap category
Small-cap
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Employees
41
Investor relations
-
SEC filings
CEO
Christopher Schelling
Country
USA
City
Newton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Acer Therapeutics Inc. (ACER) closed at $2.28 in the latest trading session, marking a -1.72% move from the prior day.
February 1, 2023
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update...
January 31, 2023
Now’s a great time to start considering which micro-cap stocks to buy. Generally, micro-caps are stocks with a market capitalization of less than $300 million. With a cap like that, the company doesn’...
January 27, 2023
In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.40, marking a +1.27% move from the previous day.
January 25, 2023
Acer Therapeutics Inc. (ACER) closed at $2.39 in the latest trading session, marking a -0.83% move from the prior day.
January 19, 2023
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
January 19, 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
January 18, 2023
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
January 16, 2023
NEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commerciali...
January 9, 2023
POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancerNEWTON, Mass., Jan. 05, 2023...
January 5, 2023
Next page